[Review and revision of guidelines for ovarian cancer treatment in Japan].
A survey of members of the Japan Society of Gynecologic Oncology revealed that 93% of the members use the present Guideline for Ovarian Cancer Treatment in practice. There is an international consensus about first-line treatment for ovarian cancer. In contrast, the treatment for sex-cord stromal tumor, which is rare, and recurrent cancer are not standardized. In addition, management for borderline malignant tumor has been controversial. The new revision incorporates a new chapter regarding these matters. The revised Guideline may be more useful. We hope that re-examination and future revisions will be made to continually update the Guideline.